GlassScriptPhysician profile
Stephen Thomas Kondash
NPI 1962404186
$5,483.83
in general payments reported to CMS, 2019-2025
31 companies · $1,231 in 2025
The $1,231 reported for 2025 was more than what 82% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,001 · 2020: $502 · 2021: $588 · 2022: $560 · 2023: $1,068 · 2024: $534 · 2025: $1,231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,833.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $805.78 | 2020-2025 | Hydrus Microstent, Clareon, Centurion |
| Johnson & Johnson Surgical Vision, INC. | $505.39 | 2019-2024 | Tecnis Iol |
| Abbvie INC. | $349.93 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $340.22 | 2019-2025 | Cequa, Xelpros |
| Allergan, INC. | $297.00 | 2019-2022 | |
| Omeros Corporation | $282.21 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $215.44 | 2022-2025 | Miebo, Xiidra |
| Ivantis, INC | $211.63 | 2021 | |
| Ocular Therapeutix, INC. | $203.40 | 2020-2024 | Dextenza |
| Novartis Pharmaceuticals Corporation | $192.03 | 2019-2023 | |
| Carl Zeiss Meditec, INC. | $178.13 | 2019 | |
| Aerie Pharmaceuticals, INC. | $177.62 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $167.33 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $166.33 | 2019-2021 | |
| Rxsight INC | $160.55 | 2023-2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $158.23 | 2019-2025 | Idosetr |
| Harrow Eye, LLC | $138.48 | 2024-2025 | Vevye |
| Biotissue Holdings INC. | $136.31 | 2023 | |
| Dompe US, INC. | $111.65 | 2025 | Oxervate |
| Thea Pharma INC. | $111.21 | 2024-2025 | Iyuzeh |
| Topcon Healthcare, INC. | $85.93 | 2019 | |
| Rayner Intraocular Lenses Limited | $83.55 | 2022-2025 | Rayone Emv, Rayone Aspheric, Rayone Spheric |
| Amgen INC. | $82.00 | 2024-2025 | Tepezza |
| Sight Sciences, INC. | $67.20 | 2022-2023 | Omni Surgical System |
| Horizon Therapeutics Plc | $59.06 | 2019-2023 | Tepezza |
| Halozyme INC | $54.86 | 2020-2025 | Hylenex Recombinant |
| New World Medical,INC. | $37.45 | 2019-2023 | |
| Shire North American Group INC | $35.12 | 2019 | |
| Astellas Pharma US INC | $30.89 | 2023 | |
| Akorn, INC. | $19.80 | 2020 | |
| Kala Pharmaceuticals, INC. | $19.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Kondash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.